James T. Parsons net worth and biography

James Parsons Biography and Net Worth

Director of Oncolytics Biotech

James Parsons is a life sciences industry veteran with over two decades of executive experience. He served as the Chief Financial Officer (CFO) of Trillium Therapeutics Inc. (TSX / NASDAQ: TRIL) from August 2011 through its acquisition by Pfizer in November 2021 for an aggregate purchase price of approximately $2.2 billion. Prior to his time at Trillium, Mr. Parsons provided financial consulting services as the President of Empar Management. He also previously served as Vice President, Finance, at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences (formerly Amorfix Life Sciences Ltd.), and CFO and Vice President, Finance and Administration, at Aptose Biosciences Inc. (formerly Lorus Therapeutics). Mr. Parsons has been a Director and the Chair of the Audit Committees of Sernova Corp. (TSX: SVA) and DiaMedica Therapeutics Inc. (NASDAQ: DMAC) since 2012 and 2015, respectively.

What is James T. Parsons' net worth?: The estimated net worth of James T. Parsons is at least $35.85 thousand as of March 11th, 2026. Mr. Parsons owns 41,849 shares of Oncolytics Biotech stock worth more than $35,848 as of August 28th. This net worth estimate does not reflect any other assets that Mr. Parsons may own. Learn More about James T. Parsons' net worth.
How do I contact James T. Parsons?: The corporate mailing address for Mr. Parsons and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on James T. Parsons' contact information.
Has James T. Parsons been buying or selling shares of Oncolytics Biotech?: James T. Parsons has not been actively trading shares of Oncolytics Biotech over the course of the past ninety days. Most recently, on Wednesday, March 11th, James T. Parsons bought 10,000 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $1.03 per share, with a total value of $10,300.00. Following the completion of the transaction, the director now directly owns 41,849 shares of the company's stock, valued at $43,104.47. Learn More on James T. Parsons' trading history.
Who are Oncolytics Biotech's active insiders?: Oncolytics Biotech's insider roster includes Andrew Aromando (Chief Business Officer), Deborah Brown (Director), Allison Hagerman (Chief Technology Officer), James Parsons (Director), and Bernd Seizinger (Director). Learn More on Oncolytics Biotech's active insiders.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

James T. Parsons Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/11/2026	Buy	10,000	$1.03	$10,300.00	41,849

James T. Parsons Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.86

$0.82

$0.86

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.86

$0.73

$1.51

Volume

671,581 shs

Average Volume

1,275,658 shs

Market Capitalization

$109.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13